TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB: “BVTI”), a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin’s lymphoma, today announced that the Company has retained the investment banking firm, ROTH Capital Partners, LLC (ROTH). ROTH has been engaged to assist Biovest in raising capital as the Company prepares to emerge from Chapter 11 reorganization.
